Center for Neuroscience and Cell Biology, CNC-CIBB, University of Coimbra, Coimbra, Portugal.
UnIGENe, IBMC -Institute for Molecular and Cell Biology, Porto, Portugal.
J Alzheimers Dis. 2020;78(2):587-601. doi: 10.3233/JAD-200556.
Mild cognitive impairment (MCI) has been considered as a pre-dementia stage, although the factors leading to Alzheimer's disease (AD) conversion remain controversial.
Evaluate whether TOMM40 poly-T (TOMM40' 523) polymorphism is associated with the risk and conversion time from MCI to AD and secondly with AD cerebrospinal fluid (CSF) biomarkers, disentangling the APOE genotype.
147 AD patients, 102 MCI patients, and 105 cognitively normal controls were genotyped for poly-T polymorphism. MCI patients were subdivided into two groups, the group of patients that converted to AD (MCI-AD) and the group of those that remained stable (MCI-S).
TOMM40' 523 L allele was significantly more frequent in the MCI-AD group and having at least one L allele significantly increased the risk of conversion from MCI to AD (OR = 8.346, p < 0.001, 95% CI: 2.830 to 24.617). However, when adjusted for the presence of APOEɛ4 allele, both the L allele and ɛ4 allele lost significance in the model (p > 0.05). We then analyzed the APOEɛ4-TOMM40' 523 L haplotype and observed that patients carrying this haplotype had significantly higher risk (OR = 5.83; 95% CI = 2.30-14.83) and mean lower times of conversion to AD (p = 0.003). This haplotype was also significantly associated with a biomarker profile compatible with AD (p = 0.007).
This study shows that the APOEɛ4-TOMM40' 523 L haplotype is associated with a higher risk and shorter times of conversion from MCI to AD, possibly driven by CSF biomarkers and mitochondrial dysfunction.
轻度认知障碍 (MCI) 被认为是痴呆前阶段,尽管导致阿尔茨海默病 (AD) 转化的因素仍存在争议。
评估 TOMM40 多态性(TOMM40' 523)是否与从 MCI 向 AD 转化的风险和转化时间相关,其次与 AD 脑脊液 (CSF) 生物标志物相关,同时区分 APOE 基因型。
对 147 名 AD 患者、102 名 MCI 患者和 105 名认知正常对照进行多态性检测。将 MCI 患者分为两组,即转化为 AD 的 MCI 患者 (MCI-AD) 和稳定的 MCI 患者 (MCI-S)。
MCI-AD 组中 TOMM40' 523 L 等位基因的频率明显更高,至少携带一个 L 等位基因显著增加了从 MCI 向 AD 转化的风险 (OR = 8.346, p < 0.001, 95% CI: 2.830 至 24.617)。然而,当调整 APOEɛ4 等位基因的存在时,L 等位基因和ɛ4 等位基因在模型中均失去了意义 (p > 0.05)。然后,我们分析了 APOEɛ4-TOMM40' 523 L 单倍型,观察到携带该单倍型的患者具有显著更高的风险 (OR = 5.83; 95% CI = 2.30-14.83),向 AD 转化的平均时间更短 (p = 0.003)。该单倍型也与与 AD 一致的生物标志物特征显著相关 (p = 0.007)。
这项研究表明,APOEɛ4-TOMM40' 523 L 单倍型与从 MCI 向 AD 转化的风险增加和转化时间缩短相关,可能由 CSF 生物标志物和线粒体功能障碍驱动。